Trevi Therapeutics provides update on Haduvio’s clinical development program

Trevi Therapeutics provided updates on its clinical development programs for investigational therapy Haduvio – oral nalbuphine ER – for the treatment of chronic cough in idiopathic pulmonary fibrosis – IPF – and refractory chronic cough – RCC. The Phase 2b CORAL trial for the treatment of chronic cough in patients with IPF has enrolled 50% of the targeted study enrollment, which is the number of patients needed for the pre-specified sample size re-estimation. The outcome of the SSRE result is expected in December. Assuming no adjustments are made to the sample size, topline results are expected in the first half of 2025. The Human Abuse Potential completed dosing. Topline results are expected in December. The Phase 2a RIVER trial for the treatment of RCC has enrolled the planned sample size but remains open to allow for additional enrollment in both arms to approximate the stratification targets. Topline results are now expected in Q1 2025.